Related references
Note: Only part of the references are listed.Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer
G. E. Konecny et al.
GYNECOLOGIC ONCOLOGY (2021)
The forefront of ovarian cancer therapy: update on PARP inhibitors
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2020)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
IGF system targeted therapy: Therapeutic opportunities for ovarian cancer
J. A. L. Liefers-Visser et al.
CANCER TREATMENT REVIEWS (2017)
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
C. S. Fuchs et al.
ANNALS OF ONCOLOGY (2015)
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)
Nasser H. Hanna et al.
CANCER (2015)
The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?
Caitrin Crudden et al.
GROWTH HORMONE & IGF RESEARCH (2015)
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
Francesco Sclafani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
Francesco Sclafani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
G. V. Scagliotti et al.
ANNALS OF ONCOLOGY (2015)
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Eric Van Cutsem et al.
CLINICAL CANCER RESEARCH (2014)
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2014)
Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non-Small-Cell Lung Cancer
Corey J. Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice
Gordon Moody et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial
Teresa Moran et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2014)
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
A. L. Cohn et al.
ANNALS OF ONCOLOGY (2013)
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
John F. R. Robertson et al.
LANCET ONCOLOGY (2013)
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
H. L. Kindler et al.
ANNALS OF ONCOLOGY (2012)
Phase II Study of Ganitumab, a Fully Human Anti-Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors
William D. Tap et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells
Niels Eckstein et al.
CANCER RESEARCH (2009)
Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer
Christophe Blanquart et al.
BIOCHEMICAL PHARMACOLOGY (2008)
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
Paul Haluska et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska et al.
CLINICAL CANCER RESEARCH (2007)
Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation
Samira Benyoucef et al.
BIOCHEMICAL JOURNAL (2007)
The EGF receptor interacts with the type 1 IGF receptor and regulates its stability
Johann Riedemann et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
Floriana Morgillo et al.
CANCER RESEARCH (2006)
Targeting insulin-like growth factor pathways
D Yee
BRITISH JOURNAL OF CANCER (2006)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
Y Wang et al.
MOLECULAR CANCER THERAPEUTICS (2005)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved
G Pandini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor
AP Gilmore et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells
ME Balañá et al.
ONCOGENE (2001)
Share Paper
